Catalyst Wire Dossier Catalyst Wire Dossier

Vesleteplirsen (SRP-5051)

vesleteplirsen · Sarepta Therapeutics, Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Vesleteplirsen (SRP-5051), covering 2025-03-10 to 2025-03-10. Get the full timeline:

Most recent: Clinical Trial Update: Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Then Dose Expansion (Part B) in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment [Phase 2]

See pricing